Journal of Microbiology Research
p-ISSN: 2166-5885 e-ISSN: 2166-5931
2012; 2(4): 68-72
doi: 10.5923/j.microbiology.20120204.01
Anna L. Njunda 1, Anselm A. Ewang 2, Lucien-Henri F. Kamga 1, Dickson S. Nsagha 3, Jules-Clement N. Assob 4, David A. Ndah 1, Tebit E. Kwenti 1
1Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, Buea, Box 63, Cameroon
2Maflekumen Higher Institute Of Health Sciences, Tiko, Box 262, Cameroon
3Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, Buea, Box 63, Cameroon
4Department of Biomedical Sciences, Faculty of Health Sciences, University of Buea, Buea, Box 63, Cameroon
Correspondence to: Tebit E. Kwenti , Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, Buea, Box 63, Cameroon.
Email: |
Copyright © 2012 Scientific & Academic Publishing. All Rights Reserved.
Respiratory tract aspergillosis refers to fungi infections of the respiratory tract caused by Aspergillus species. Respiratory tract aspergillosis has clinical and radiological characteristics which are very similar to tuberculosis thereby making the disease easily misdiagnosed and mistreated as tuberculosis. This prompted us to investigate the prevalence of respiratory tract Aspergillus sp. in the sputum of patients suspected of pulmonary tuberculosis and to study the anti-fungal susceptibility of the isolated Aspergillus strains. Two hundred sputa samples were studied for Aspergillus sp. and M. tuberculosis. Direct microscopy and fungal culture was done on two sets of Sabouraud Dextrose agar. Analysis for Acid-Fast Bacilli (AFB) was done by the Auramine-phenol fluorochrome technique. Aspergillus sp were isolated from 30(15%) patients; A. fumigatus was isolated in 10 (5%) patients while A. niger, A. flavus, and A. terreus were isolated from 9 (4.5%), 6 (3%) and 5 (2.5%) patients respectively. M. tuberculosis was found in 27(13.5%) and a co-infection of 9(4.5%) was observed.Using the broth micro dilution technique, the minimum inhibitory concentrations (MICs) for Aspergillus sp for nystatin, itraconazole and amphotericin B ranged between 0.12- >16 μg/ml, 0.06- >16 μg/ml and 0.12- 0.5 μg/ml, respectively. All the Aspergillus terreus strains were consistently sensitive to itraconazole (MIC >16 μg/ml).
Keywords: Aspergillosis, Tuberculosis, Diagnosis, Prevalence, Sensitivity Test
|
|
|
[1] | Jasmer, R.M., Nahid, P., and Hopewell, P.C., 2002, Clinical practice, Latent tuberculosis infection., The New England Journal of Medicine, 347 (23), 1860–6 |
[2] | World Health Organization. (2007). Tuberculosis. [Online].Available:http://who.int/mediacentre/factsheets/fs104/en/index.html |
[3] | Randhawa, H.S., Khan, Z.U., and Mussa, A.Y., 1996, Systemic mycoses: Today and tomorrow, In: Sharma PL, Sood OP (eds) Microbial Threats to Health in the 2Zsf Century., Amsterdam: Scientific Communication International Ltd, 59-70 |
[4] | Steinbach, W.J., 2005, Pediatric aspergillosis disease and treatment differences in children., Pediatric Infectious Disease Journal, 24,358–364 |
[5] | Cheesbrough M., 2006, District laboratory practice in tropical countries part 2, Second edition., Cambridge University Press, London, P. 41 -42 |
[6] | Cheesbrough M., 2006, District laboratory practice in tropical countries part 2, Second edition., Cambridge University Press, London, P. 73 |
[7] | Shahid, M. and Malik, A., 2002, A comparative study of two culture media for the growth of pathogenic Aspergillus species: An aid to early diagnosis., Bio-Science Res. Bulletin, 18, 65-70 |
[8] | Collier, L., Balows A., and Sussman, M., 1998, Topley and Wilson’s Microbiology and Microbial Infections, 9th ed. London: Arnold |
[9] | Ingroff, A.E., Bartlett M., and Bowden R., 1997, Multicenter evaluation of proposed standardized procedure for anti fungal susceptibility testing of filamentous fungi., Journal Clinical Microbiology, 35, 139-143 |
[10] | National Committee for Clinical Laboratory Standards, 1992, Reference method for broth dilution susceptibility antifungal testing for yeast. Proposed standard, Document M27-P., National Committee for Clinical Laboratory Standards, Villanova, Pa |
[11] | Malik, A., Shahid, M. and Bhargava, R., 2003, Prevalence of Aspergillosis in bronchogenic carcinoma., Indian Journal of Pathology Microbiology, 46, 507-510 |
[12] | Shahid, M., Malik, A. and Bhargava, R., 2007, Secondary Aspergillus in Bronchoalveolar Lavages (BALs) of Pulmonary Tuberculosis Patients from North-India., American-Eurasian Journal of Scientific Research, 2 (2), 97-100 |
[13] | Kurhade, A.M., Deshmukh, J.M., Fule, R.P., Chande, C. and Akulwar, S., 2002, Mycological and serological study of pulmonary Aspergillosis in central India., Indian Journal of Medicine. Microbiology, 20, 141-144 |
[14] | Bakare, N., Rickerts, V., Bargon, J., Just-Nübling, G., 2003, Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis, Mycoses, 46(1-2), 19-23 |
[15] | Razmpa, E., Khajavi, M., Hadipour-Jahromi, M., and Kordbacheh, P., 2007, The prevalence of fungal infections in nasal Polyposis, Acta Medica Iranica, 45 (1), 46-50 |
[16] | Luis, M. , Manuela, C., Santiago, Q., José, F. C., Adalberto, P., Aurora, S., and Héctor, E., 2002, Serologic IgE Immune Responses Against Aspergillus fumigatus and Candida albicans in Patients With Cystic Fibrosis, CHEST,121(3), 782-788 |
[17] | Mullins, J., and Seaton, A., 1978, Fungal spores in lung and sputum, Clinical Allergy, 8, 525-533 |
[18] | Sahoo, R.C., Rao, P.V.P., Shivananda, P.O., Kumar, A., and Mohanti, L.K., 1988, A Profile of Aspergillus lung disease., J. Assoc. Phy Ind., 36, 711 |
[19] | Panda, B.N., Rosha, D. and Verma, M.,1998, Pulmonary tuberculosis: a predisposing factor for colonizing and invasive aspergillosis of lungs., Indian Journal of Tuberculosis, 45, 221-22 |
[20] | Hennequin, C., Benailly, N., Silly, C, Sorin, M., Scheinmann, P., Lenoir, G., Gaillard, j. L., and Berche, P., 1997, In Vitro Susceptibilities to Amphotericin B, Itraconazole, and Miconazole of Filamentous Fungi Isolated from Patients with Cystic Fibrosis., Antimicrobial agents and Chemotherapy, 41(9), 2064-6 |
[21] | Oakley K.L., Moore, C.B., and Denning, D.W., 1999, Comparison of In Vitro activity of Liposomal Nystatin against Aspergillus Species with those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole. Antimicrobial Agents and Chemotherapy, 43(5), 1264-1266 |